John Oyler Sells 48,316 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 48,316 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $312.25, for a total value of $15,086,671.00. Following the completion of the sale, the chief executive officer directly owned 9,180 shares in the company, valued at $2,866,455. This trade represents a 84.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Down 1.0%

Shares of ONC stock opened at $327.21 on Thursday. The firm has a fifty day moving average price of $293.14 and a 200-day moving average price of $309.42. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market cap of $35.90 billion, a price-to-earnings ratio of 73.20 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion for the quarter. As a group, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current year.

Wall Street Analyst Weigh In

ONC has been the topic of a number of research reports. Truist Financial lifted their price target on shares of BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Citizens Jmp reaffirmed a “market outperform” rating and issued a $396.00 price target on shares of BeOne Medicines in a research note on Wednesday, July 1st. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research note on Monday. Finally, Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $394.00.

Institutional Investors Weigh In On BeOne Medicines

A number of large investors have recently bought and sold shares of the company. EFG International AG acquired a new stake in shares of BeOne Medicines in the fourth quarter worth $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines in the second quarter valued at approximately $35,000. CWM LLC boosted its holdings in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines during the 4th quarter valued at about $61,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.